Carol L. Brosgart, M.D. serves on the boards of privately held companies and public, not-for-profit, domestic, and global health organizations. She is a member of the Board of Directors of Galmed Pharmaceuticals, Ltd. and Abivax. Previously, she served as a member of Tobira Therapeutics’s Board of Directors from September 2009 until Allergan acquired it in November 2016; and, she was formerly on the Board of Juvaris, a vaccine company until Bayer Company acquired its assets. She is a consultant to Allergan, Dynavax, and a number of biotechnology companies in the areas of liver disease and infectious diseases. Dr. Brosgart is the Chair of the Scientific Advisory Committee for Hepion (formerly “ContraVir”), a biotechnology company working in the area of HBV Cure. She also serves on the Board of the American Liver Foundation (ALF) and the ALF Medical and Scientific Advisory Board, Northern California Chapter, the Steering Committee of the National Viral Hepatitis Roundtable, the Executive Committee of the Forum for Collaborative Research, and the Steering Committee of the HBV Cure Group at the Forum. She is a member of the Board of the Hepatitis B Foundation (HBF); serves on the Medical and Scientific Advisory Committee of the Hepatitis B Foundation; and, is the Research Integrity Officer for the Hepatitis B Foundation and the Baruch S. Blumberg Institute. She served for many years on the Boards of the SF AIDS Foundation and the Pangaea Global AIDS Foundation. She is active in the public policy arena for the following professional organizations: AASLD and IDSA/HIVMA. Dr. Brosgart served as Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC and the Viral Hepatitis Action Coalition at the CDC Foundation from 2011 to 2013. Dr. Brosgart has also served as a member on the faculty of the School of Medicine at the University of California, San Francisco for the past four decades, where she is a Clinical Professor of Medicine, Biostatistics, and Epidemiology in the Division of Global Health and Infectious Diseases. From March 2011 until August 2011, Dr. Brosgart served as Chief Medical Officer at biotechnology company Alios BioPharma, Inc. Prior to Alios, Dr. Brosgart served as Senior Vice President and Chief Medical Officer of Children’s Hospital & Research Center in Oakland, California, from 2009 until February 2011. Previously, she served for eleven years, from 1998 until 2009, at the biopharmaceutical company Gilead Sciences, Inc., where she held a number of senior management roles, most recently as Vice President, Public Health and Policy and earlier as Vice President, Clinical Research and Vice President, Medical Affairs and Global Medical Director, Hepatitis. She led the clinical development of a number of agents at Gilead, including Viread and Hepsera. Prior to Gilead, Dr. Brosgart worked for more than 20 years in clinical care, research, and teaching at several Bay Area medical centers. She was the founder and Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California, from 1987 until 1998 and served as the Medical Director of Central Health Center, Oakland, California, of the Alameda County Health Care Services Agency. Dr. Brosgart received a B.S. in Community Medicine from the University of California, Berkeley, and received an M.D. from the University of California, San Francisco. Her residency training was in pediatrics, public health, and preventive medicine at UCSF and UC Berkeley School of Public Health. She has published extensively in the areas of HIV, HBV, CMV, and liver disease.
Dr. Dybul has served as a Professor in the Department of Medicine at Georgetown University Medical Center, and the Faculty Co-Director of the Center for Global Health and Quality since June of 2017. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher, and administrator, most recently as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis, and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. Dr. Dybul was one of the founding architects in the formation of the U.S. President’s Emergency Plan for AIDS Relief, better known as PEPFAR. After serving as Chief Medical officer, Assistant, Deputy, and Acting Director, he was appointed as its leader in 2006, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009. Earlier in his career, after graduating from Georgetown Medical School in Washington D.C., Dr. Dybul joined the National Institute of Allergy and Infectious Diseases, as a research fellow under director Dr. Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination antiretroviral therapy in Africa. Dr. Dybul has written extensively in scientific and policy literature and has received several Honorary Degrees and awards, including a Doctor of Science, Honoris Causa, from Georgetown University. Dr. Dybul is a member of the national academy of medicine. We believe Dr. Dybul’s extensive high-level clinical and institutional experience in the field of HIV/AIDS qualifies him to serve as a director.
Dr. Hardy currently serves as Senior Director of Evidence-based Practices, ACTG clinical research site (CRS) leader, MACS co-investigator, and HIV/primary care provider at Whitman-Walker Health in Washington, D.C., and also holds an Adjunct Professor of Medicine appointment at Johns Hopkins University School of Medicine in Baltimore. Dr. Hardy currently serves as Chair-elect of the Board of Directors of HIV Medicine Association (HIVMA), Chair of the Education Committee of the American Academy of HIV Medicine (AAHIVM), and Editor-in-Chief of AAHIVM’s comprehensive textbook Fundamentals of HIV Medicine for the HIV Specialist, published in 2012 and 2016. He previously served as Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and Professor of Medicine at the David Geffen School of Medicine at UCLA, and just prior to joining Whitman-Walker, he was Chief Medical Officer for Calimmune, a biotechnology company investigating gene-modified CD4+ T cells and hematopoietic stem cells as a potential therapy for HIV infection.
Professor Peter Revill is a senior medical scientist and Head of the Molecular Virology laboratory within the Division of Research and Molecular Development at VIDRL, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity. He was appointed on contract in 2004, given tenure in 2007, and promoted to Section Head in 2011. He has over 25 year’s experience as a molecular virologist and is an internationally recognized expert on hepatitis B virus (HBV) virology and pathogenesis, particularly the contribution of HBV variants and the role of HBV splicing in disease progression and treatment response. He has had a very productive research career with over 80 publications and has been a lead or senior author on publications in highly respected journals, including GUT, Nature Reviews Gastroenterology and Hepatology, Hepatology, The Journal of Hepatology, The Lancet Gastroenterology and Hepatology, and The Journal of Virology.
Prof. Revill has a strong national and international reputation in HBV virology and pathogenesis. In 2015, with Professor Stephen Locarnini and Professor Fabien Zoulim, he initiated the global HBV cure initiative, the “International Coalition to Eliminate HBV” (ICE-HBV), with a Perspectives paper published in “Nature Reviews Gastroenterology and Hepatology”. In 2016, he was elected founding Chair of the ICE-HBV Governing Board (http://ice-hbv.org/), until Professor Zoulim succeeded him in this role in 2020. He also led the publication of the ICE-HBV Global Scientific Strategy for HBV cure (Revill et al., The Lancet Gastro. Hep. 2019). Prof Revill has contributed significantly to our understanding of HBV pathogenesis, particularly the role of genotypes and HBV variants in disease pathogenesis, HIV-HBV co-infection, and regulation of innate immune responses. He led the team which showed that spliced HBV variants in serum are strongly associated with liver cancer (Bayliss J. Hepatol. 2013), following up from his earlier studies published in Hepatology (Preiss et al., 2008) and has recently used RNASeq to identify HBV splice variants across multiple HBV genotypes in cell culture and patients (Lim et al, Microbial Genomics, 2020). His team was also the first to use HBV genome length deep sequencing to show that HBV BCP variants were associated with reduced likelihood of functional cure in the setting of antiviral therapy (Bayliss et al, GUT, 2016). Most recently his team has pioneered the use of genome length haplotype analysis to study HBV variants across multiple genotypes and phases of HBV natural history, identifying numerous highly conserved sequences in the HBV genome (Wagner et al, Hepatology, 2020), which his group is currently assessing in functional studies.
Professor of Medicine, Lyon University, Institut Universitaire de France Medical Director, Hepatology Department at the Hospices Civils de Lyon, France. Scientific Director, Viral Hepatitis Research Laboratory, INSERM U1052, Cancer Research Center of Lyon, France.
Fabien Zoulim obtained his M.D. in Gastroenterology and Hepatology in Lyon Medical School in 1991. He has also obtained a Ph.D. in Molecular and Cellular Biology and was trained as a post-doctoral researcher at Fox Chase Cancer Center in Philadelphia. He
is a Professor of Medicine at Lyon I University since 1997. He is Head of the Hepatology Department at the Hospices Civils de Lyon and Head of the Viral Hepatitis Research Laboratory of INSERM Unit 1052. Dr. Zoulim is currently Associate Editor for GUT. He also served as a Governing Board member of the European Association for the Study of the Liver (EASL). Dr. Zoulim received the William Prusoff award of the International Society for Antiviral Research. He is currently coordinating the ANRS “HBV cure” Task Force in France and the “IP-cure-B” project within the EU H2020 work program. He co-founded the International Coalition to Eliminate HBV (ICE-HBV: http//:www.ice-
hbv.org). He has published more than 500 articles (Web of Science H index 81).